Literature DB >> 3828191

Pharmacokinetics of intravenous amodiaquine.

N J White, S Looareesuwan, G Edwards, R E Phillips, J Karbwang, D D Nicholl, C Bunch, D A Warrell.   

Abstract

Amodiaquine hydrochloride (3 mg base kg-1) was given by constant rate intravenous injection over 10 min to seven healthy adult male volunteers, and by constant rate infusion (10 mg base kg-1) over 4 h to 10 adult patients admitted to hospital with falciparum malaria. After intravenous injection in volunteers there was considerable variation in plasma concentration profiles between subjects; peak plasma concentrations ranged between 65 and 1921 ng ml-1. A biexponential equation was fitted to the plasma concentration time data and the following estimated pharmacokinetic parameters (geometric mean; range) were derived; lambda 1 = 24.4 (7.6-95.0) h-1, lambda 2 = 0.33 (0.12-0.79) h-1, V1:1.1 (0.3-3.6) 1 kg-1, Vss: 17.4 (2.3-95.9) 1 kg-1 and systemic clearance 13.0 (4.7-56.6) 1 kg-1 h-1. After intravenous infusion there was also considerable variability between patients with post-infusion plasma concentrations ranging between 82 and 836 ng ml-1. The plasma concentration-time profiles were biphasic with the following estimated pharmacokinetic parameters (geometric mean; range) alpha = 1.87 (0.60-8.52) h-1, beta = 0.069 (0.021-0.265) h-1, V1: 4.6 (0.5-29.3) 1 kg-1, Vss: 38.3 (3.7-127.9) 1 kg-1 and systemic clearance CL (1.6-17.3) 1 kg-1 h-1. There was no measurable long terminal elimination phase, and the principal metabolite desethyl amodiaquine was not detected in the plasma samples. There was no serious toxicity in either group. During intravenous injection there was a significant fall in systolic blood pressure in four subjects (mean fall 16 mm Hg) but there was no significant change in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3828191      PMCID: PMC1386059          DOI: 10.1111/j.1365-2125.1987.tb03020.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  High-performance liquid chromatographic analysis of amodiaquine in human plasma.

Authors:  G W Mihaly; D D Nicholl; G Edwards; S A Ward; M L Orme; D A Warrell; A M Breckenridge
Journal:  J Chromatogr       Date:  1985-01-11

2.  Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquine-resistant falciparum malaria.

Authors:  S Looareesuwan; R E Phillips; N J White; J Karbwang; Y Benjasurat; P Attanath; D A Warrell
Journal:  Lancet       Date:  1985-10-12       Impact factor: 79.321

3.  Plasmodium falciparum in Kisumu, Kenya: differences in sensitivity to amodiaquine and chloroquine in vitro.

Authors:  H C Spencer; T Kipingor; R Agure; D K Koech; J D Chulay
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

4.  Numerical integration simulation programs for the microcomputer.

Authors:  J R Koup; D R Benjamin
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.

Authors:  W M Watkins; D G Sixsmith; H C Spencer; D A Boriga; D M Kariuki; T Kipingor; D K Koech
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

8.  Quinine disposition kinetics.

Authors:  N J White; P Chanthavanich; S Krishna; C Bunch; K Silamut
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

9.  Intravenous amodiaquin (camoquin) in naturally acquired and induced malaria.

Authors:  E PAYNE; V M VILLAREJOS; E A SHARP; J W REINERTSON; W S WILLE
Journal:  Am J Trop Med Hyg       Date:  1951-11       Impact factor: 2.345

10.  Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans.

Authors:  F C Churchill; L C Patchen; C C Campbell; I K Schwartz; P Nguyen-Dinh; C M Dickinson
Journal:  Life Sci       Date:  1985-01-07       Impact factor: 5.037

View more
  16 in total

1.  Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.

Authors:  F Verdier; E Pussard; F Clavier; J Le Bras; C Gaudebout
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

Authors:  I Cavaco; J Strömberg-Nörklit; A Kaneko; M I Msellem; M Dahoma; V L Ribeiro; A Bjorkman; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

Review 3.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Authors:  Richard T Eastman; David A Fidock
Journal:  Nat Rev Microbiol       Date:  2009-11-02       Impact factor: 60.633

Review 4.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria.

Authors:  E Pussard; F Verdier; F Faurisson; J M Scherrmann; J Le Bras; M C Blayo
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

7.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.

Authors:  Joel Tarning; Palang Chotsiri; Vincent Jullien; Marcus J Rijken; Martin Bergstrand; Mireille Cammas; Rose McGready; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White; Francois Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

9.  Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

Authors:  Sofia Friberg Hietala; Achuyt Bhattarai; Mwinyi Msellem; Daniel Röshammar; Abdullah S Ali; Johan Strömberg; Francis W Hombhanje; Akira Kaneko; Anders Björkman; Michael Ashton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-10       Impact factor: 2.745

10.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.